Company Uses Intravenous Stem Cells to Successfully Treat Alzheimer’s

Company Uses Intravenous Stem Cells to Successfully Treat Alzheimer’s

Stem Cells For Alzheimer'sAn intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer's disease has been successfully performed by Stemedica International, a subsidiary of Stemedica Cell Technologies, developing stem cell therapies for Alzheimer's disease and dementia.

The first results of the experiment were presented at the Alzheimer’s Association International Conference in Copenhagen, Denmark, on July 14, 2014, and demonstrated a more than 30-percent decrease in amyloid beta (Abeta) plaques in the brain of transgenic animals treated with Stemedica itMSCs compared to the control group, which was administrated with lactated Ringer’s solution (LRS).

“Pre-clinical results show Stemedica International’s treatment reduces the amount of plaque as much as the best drug candidates to manage Abeta amyloidosis,” explained Stemedica International’s Chief Scientist Tristan Bolmont, Ph.D. “Most importantly, our itMSC treatment did not result in side effects, such as cerebral amyloid angiopathy and micro-hemorrhages.”

[adrotate group="3"]

More information will be shared during Dr. Bolmont's talk at the Stem Cells Regenerative Medicine Congress 2014, taking pla

Subscribe or to access all post and page content.